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Abstract 4 
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized 5 
by increased mortality and associated with metabolic disorders including dyslipidaemia, 6 
insulin resistance and cachexia. Since the metabolomic profile is known to vary in 7 
response to different inflammatory conditions, those metabolite analysis could 8 
substantially improve diagnosis and prognosis.  9 
Objective: To analyses the urine metabolic profile and assess to its correlation with 10 
body composition parameters and disease activity of RA patients.  11 
Methods: Seventy-nine RA patients, according to ACR/EULAR 2010 classification 12 
criteria, aged between 40 and 70 years, were recruited and followed for 12 months. 13 
Disease activity, body composition, fatigue and urine metabolome were measured. 14 
Body composition was assessed by total body dual-energy x-ray absorptiometry (DXA) 15 
for measurement of appendicular lean mass index (ALMI). Disease activity was 16 
assessed by Disease Activity Score-28 (DAS28) with erythrocyte sedimentation rate 17 
(ESR). Fatigue as assessed by the Functional Assessment of Chronic Illness Therapy 18 
(FACIT). Nuclear Magnetic Ressonance (NMR) spectroscopy measurements were 19 
performed to evaluate the profile of metabolic changes during the disease 20 
development, resulting in the identification of 48 metabolites in urine collected at the 21 
baseline and after one year after. Frequency analysis, Pearson Correlation and 22 
Multivariate data analysis with orthogonal projections to latent structures (OPLS) 23 
method were performed and a statistical significance was considered as p<0.05. 24 
Results: The study population was characterized by the majority of women 25 
(86.7%), mean age 56 years old, around 80% with anti-CPP and Rheumatoid 26 
Factor reagent. During the one year of follow-up, there was no huge substantial 27 
variation in the DAS28 measurement (baseline: 3,8, after 12 months: 4,0). It is 28 
By for this reason, we belivebelieve that we could not find any significant 29 
correlation between the metabolome pattern and DAS28 score (p>0.05). 30 
However, Tthere was a significant increase of methyl-histidine, creatinine, L-31 
serine and urea by during the development of the disease, metabolites that are 32 
involved in the muscular muscle-related metabolismconstitutions pathways. . 33 
Fatigue was positively correlated with L-serine/creatinine (r: - 0,4, p<0.001). 34 
Appendicular lean mass index (ALMI) also presented showed a difference when 35 
which correlated to with the increase of urea and creatinine (r: 0,3, p<0.019).  36 
Conclusion: The potential biomarkers indicated that the RA metabolic 37 
disturbance might be associated with inflammation, injury, fatigue and amino 38 
acid metabolism. Those These findings suggest that urine metabolome analysis 39 
may be an interesting approach to monitoring rheumatological disease related 40 
to muscle changes and fatigue, which are of major concern to patients, and this 41 
that could be more further explored in future trialsstudies. 42 
